Latest news

• Roche’s Soliris rival Enspryng bags FDA approval

  Enspryng ( satralizumab) has been approved to treat adult patients living with anti-aquaporin-4 (AQP4) antibody positive NMOSD, a rare autoimmune disorder of the central nervous system which is often misdiagnosed

• Roche’s Soliris rival satralizumab scores in phase 3 study

  The results from Roche’s pivotal phase 3 study of  satralizumab, SakuraSky, were published in the New England Journal of Medicine (NEJM). ... The detailed results showed that satralizumab reduced the risk of patients experiencing protocol-defined

• US, EU regulators start review of Roche’s Soliris rival satralizumab

  Interleukin-6-targeting antibody satralizumab has been filed for approval based on two phase 3 trials which show that it can reduce relapses in NMOSD patients. ... Viela thinks inebilizumab has a dosing advantage over both Soliris and satralizumab as it

• Roche presents new data in NMOSD, could challenge Alexion's Soliris

  Reduced risk of relapse by 55%. Roche has presented new data on satralizumab for neuromyelitis optica spectrum disorder (NMOSD), setting it up for a potential market battle with Alexion’s Soliris. ... The positive phase 3 study results show that

• Medimmune-born Viela files $150m IPO, eyes first product launch

  Meanwhile, Japan’s Chugai also has positive phase 3 data with its NMOSD candidate satralizumab, an interleukin-6 inhibitor partnered with Roche.